Literature DB >> 3111321

Evaluation of blood donors with elevated serum alanine aminotransferase levels.

L S Friedman, J L Dienstag, E Watkins, C A Hinkle, J A Spiers, S V Rieder, C E Huggins.   

Abstract

We evaluated 100 asymptomatic blood donors with serum alanine aminotransferase (ALT) levels exceeding 0.83 mu kat/L, for evidence of liver disease or risk factors for non-A, non-B hepatitis and followed serum ALT levels for another 6 months. In 92 donors completing the study, ALT elevations occurred once in 33%, intermittently in 36%, persistently in 28%. Twenty-two donors were obese, 5 had clinical and biochemical evidence of alcoholic liver disease, and 45 drank alcohol regularly; 1 had hemochromatosis, and another, myopathy. In 22 no cause for elevated serum ALT levels was found. The presence or absence of risk of acquiring hepatitis did not correlate with the pattern of ALT elevations or the identification of another cause for the elevated ALT levels. In 92 blood donors with an initially elevated ALT level, two-thirds have intermittent or persistent elevations; most approximately 20% have no apparent cause for the elevations other than possible non-A, non-B hepatitis. These findings may be helpful in counseling and following blood donors with elevated ALT levels.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3111321     DOI: 10.7326/0003-4819-107-2-137

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  17 in total

1.  Obesity and hepatotoxins as risk factors for fatty liver disease.

Authors:  M Hodgson; D H van Thiel; B Goodman-Klein
Journal:  Br J Ind Med       Date:  1991-10

2.  Reexamining transaminase elevation in Phase I clinical trials: the importance of baseline and change from baseline.

Authors:  Zhaohui Cai; Anastasia M Christianson; Lars Ståhle; Marianne Keisu
Journal:  Eur J Clin Pharmacol       Date:  2009-06-25       Impact factor: 2.953

3.  Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection: an AIGO study.

Authors:  A Andriulli; V Festa; G Leandro; M Rizzetto
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

4.  Probability of C282Y homozygosity decreases as liver transaminase activities increase in participants with hyperferritinemia in the hemochromatosis and iron overload screening study.

Authors:  Paul C Adams; Mark Speechley; James C Barton; Christine E McLaren; Gordon D McLaren; John H Eckfeldt
Journal:  Hepatology       Date:  2012-04-18       Impact factor: 17.425

5.  Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors.

Authors:  L W Kundrotas; D J Clement
Journal:  Dig Dis Sci       Date:  1993-12       Impact factor: 3.199

6.  Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care.

Authors:  Irene Cacciola; Riccardo Scoglio; Angela Alibrandi; Giovanni Squadrito; Giovanni Raimondo
Journal:  Intern Emerg Med       Date:  2016-09-19       Impact factor: 3.397

Review 7.  Nonalcoholic fatty liver disease.

Authors:  Z M Younossi
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

Review 8.  Controversies in liver biopsy: who, where, when, how, why?

Authors:  Lawrence S Friedman
Journal:  Curr Gastroenterol Rep       Date:  2004-02

9.  Hepatitis C-virus (HCV) antibodies in patients after kidney transplantation.

Authors:  P Baur; V Daniel; S Pomer; H Scheurlen; G Opelz; D Roelcke
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

10.  High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH.

Authors:  Masato Yoneda; Hironori Mawatari; Koji Fujita; Hiroshi Iida; Kyoko Yonemitsu; Shingo Kato; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Yasunobu Abe; Kensuke Kubota; Satoru Saito; Tomoyuki Iwasaki; Yasuo Terauchi; Shinji Togo; Shiro Maeyama; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2007-07-25       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.